+ Larger Font | - Smaller Font
Share


Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Newswire Formfree Receives Us Patent For Its Ground Breaking Approach To Credit Decisioning is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.
Search RobinsPost News & Noticias


Newswire Formfree Receives Us Patent For Its Ground Breaking Approach To Credit Decisioning | RobinsPost News & Noticias

FormFree Receives U.S. Patent for Ground-Breaking Approach to Credit Decisioning - Markets Insider


ATHENS, Ga., Oct. 13, 2020 /PRNewswire/ -- FormFree® has been granted Patent Number 10,769,723 for its proprietary 'Systems and Methods for Electr ... Read More

2020-10-13 | FormFree Receives U.S. Patent for Ground-Breaking Approach to Credit Decisioning | Press Release - Stockhouse


ATHENS, Ga. , Oct. 13, 2020 /PRNewswire/ -- FormFree ® has been granted Patent Number 10,769,723 for its proprietary 'Systems and Methods for Electronic Account Certification and Enhanced ... Read More

Envoy Medical Receives Additional Patent Protection for its Innovative Approach to Hearing Loss - Morningstar


WHITE BEAR LAKE, Minnesota , Dec. 16, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a hearing health company focused on providing hearing loss suffers ... Read More

Quantiphi Receives Patent Notice of Allowance for Key Feature in Groundbreaking AI Document Processing Platform, QDox - Morningstar


Quantiphi Receives Patent Notice of Allowance for Key Feature in Groundbreaking AI Document Processing Platform, QDox Provided by PR Newswire May 6, 2025, 5:45:00 PM ... Read More

Smileyscope Receives US Patent For Groundbreaking Innovations in Virtual Reality and Augmented Reality - Business Wire


The company currently has multiple clinical trials underway and is rapidly expanding its product offerings into additional patient segments. 511 Avenue of the Americas, #4075 New York NY 1001 1888 ... Read More

Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases - Yahoo Finance


Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development ... Read More


Blow Us A Whistle


Comments (Whistles) Designed By Disqus